Safety and Dose Finding Study of Xigris in Hemodialysis Patients
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the safety of Xigris (Drotrecogin alfa) as an
anticoagulant at different dose levels during dialysis treatment in patients with End Stage
Renal Disease (ESRD).